tumours.1' Embolisation of the spleen has had a less happy history. Treatment of the whole spleen for enlargement may produce pain, abscess formation, septicaemia, and even splenic rupture; partial embolisation may be as effective a treatment with a lower morbidity.'0
Gastrointestinal bleeding in patients who are not fit for surgery is a common and unsolved problem for which embolisation may offer help. Reuter has reported 40 successful embolisations to control such haemorrhage.'2 Bleeding from gastro-oesophageal varices complicating portal hypertension has also been successfully attacked, with access to the portal circulation by a percutaneous transhepatic route."' Nevertheless, the risks and effectiveness of this technically impressive manoeuvre must be weighed against the less invasive technique of injection of the varices through the oesophagoscope.
Angiomas, particularly those containing arteriovenous fistulae, provide another example of a surgical problem for which embolisation has shown benefits, either as the definitive treatment or as a preliminary manoeuvre to convert a difficult or impossible operation into a straightforward one.'3 Particular success has been achieved in nasal angiofibromas. ' 
In 1979 they subgrouped the children with normal variant short stature into four categories on the basis of their metabolic and short-term response to growth hormone.7 Groups one and two did not respond, while groups three and four showed responses similar to those seen in growth-hormone deficient children. The next year they reported further observations8 showing that these groups three and four consisted of children who produced a growth hormone apparently normal by immunoassay criteria but of low activity in a radioreceptor assay. Serum concentrations of somatomedin-C, measured by immunoassay, were also low. They proposed that in these children the growth hormone molecule was of an abnormal structure with low biological activity producing physiological consequences comparable with true growth hormone deficiency but normal results on conventional immunoassays. The latest paper2 shows the result of treating 20 children with normal variant short stature from the four groups and five with true growth hormone deficiency with daily human growth hormone over six months. The children in normal variant short stature groups three and four responded in a manner indistinguishable from the children with true growth hormone deficiency. In contrast, those in normal variant short stature groups one and two showed no response to long-term treatment with human growth hormone, in keeping with the earlier observations in metabolic and short-term growth-response tests. The implications of these findings are that children in groups three and four should be treated long-term with human growth hormone; as Rudman and his co-workers consider their numbers to be much greater than the numbers with true growth hormone deficiency the implications for supply of human growth hormone are clear.
We Having accepted the results, we must now try to interpret them. What type of patient has Rudman's group been seeing? The growth velocities in the six months before treatment with growth hormone averaged 1-7 cm/yr, in both the patients with growth hormone deficiency and with normal variant short stature.2 This is a remarkably low velocity, even for patients with conventional deficiency of growth hormone, and must imply considerable selection of patients. Given that these patients have been growing at a similar rate for some years, which would be expected in anything other than a recently acquired condition, then heights at entry into the study, three years earlier at the age of 6, would all have been near the 25th centile. This would indeed be a strange growth curve for any form of growth hormone deficiency with such a sudden change in growth at that age. Patients with normal variant short stature groups three and four are said by Rudman et al to have an abnormal growth hormone molecule, which would imply onset of the disorder at birth. It is hard to reconcile this hypothesis with the growth curve just described.
There is a second strange feature of the children with normal variant short stature. An earlier paper7 gave individual details of the patients' weights and heights. The normal children had weight-for-height ratios9 98 + 300 ofthat expected, if one grossly obese child (their patient 9) is excluded. As usual the children with growth hormone deficiency had a high weight-for-height at 109 + 30°of expected, as did those in normal variant short stature groups three and four. Nevertheless, children in groups one and two had weight-for-heights which were 81 + 2' of expected, only just above the conventional limits considered as indicating wasting. In fact, seven out of 19 of their patients (370/ in groups 1 and 2) could be categorised as showing severe wasting. We need to know more about these children and whether they are suffering from malnutrition or from some form of deprivation.
Finally we should turn to the epidemiological aspects. Rudman et al acknowledged that considerable selection has taken place in the definition of the study sample and that prevalence estimates are worth very little. 
